



Auditors Report on Annual Financial Results of M/s Ishita Drugs & Industries Ltd. Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

To,
Board Of Directors,
Ishita Drugs & Industries Ltd

We have audited the statement of annual financial result of M/s **Ishita drugs & industries Ltd** for the year ended 31 march, 2021. Attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (listing obligation and Disclosure requirements) Regulations, 2015. These statement is the responsibility of the company's management and has been approved by the boards of directors. This statement has been prepared on the basis of the Generally Accepted Accounting Principles and policies. Our responsibility is to express an opinion on these financial results based on our audit of such annual financial statement. Which have been prepared in accordance with the recognition and measurement principles laid down in accounting standard for interim financial reporting (Ind-AS 34), prescribed, under section 133 of the companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial result are free of material misstatement(S). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best information and according to the explanations given to us these financial result.

- (i) Are presented in accordance with the requirements of regulation 33 of SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015 in this regards and
- (ii) Give a true and fair view of the net profit and other financial information for the period from 01 April, 2020 to 31 March,2021.





Office Address :

C-10 Soham Complex,
2nd Floor, Soni ni Chawl, Cross Road,
Odhav, Ahmedabad-382415

The financial result include the result for the quarter ended March 31, 2021 being the balancing figure between audited figure in respect of full financial year and the published year to date figures upto the third quarter of the financial year, which were subject to limited review by us.

Date: 30/06/2021

Place: Ahmedabad

**For and on Behalf of
JAYMIN SHAH AND ASSOCIATES**

Mayank Sancheti
Mayank Sancheti
(Partner)
M.No.: 170863
FRN: 129406W
UDIN: 21170863AAAACZ1230

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

Audited Financial Results for the Quarter and Year Ended March 31, 2021


Amount in Lakhs except Per Share data

Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months Ended in the previous Year	Year to date figures for current year ended	Year to date figures for previous year ended
	31-Mar-21	31-Dec-20	31-Mar-20	31-Mar-21	31-Mar-20
	Audited	Un-audited	Audited	Audited	Audited
1 INCOME					
Revenue from Operations	401.89	382.98	336.51	1394.90	1483.23
Other Income	26.27	1.03	5.39	31.36	16.23
Total Income	428.16	384.01	341.90	1426.26	1499.46
2 EXPENSES					
(a) Cost of Material Consumed	226.27	272.52	219.17	956.40	1135.53
(b) Purchase of Stock-In-Trade	49.05	12.66	6.35	63.18	9.25
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	6.96	14.05	7.74	9.13	(0.27)
(d) Employee Benefit Expense	30.11	28.09	29.36	109.74	109.80
(e) Finance Cost	1.47	0.51	0.56	3.16	3.47
(f) Depreciation, Depletion and Amortisation Expense	1.30	4.44	6.05	14.61	17.75
(g) Other Expense	58.01	32.51	50.96	164.65	152.59
Total Other Expenses	58.01	32.51	50.96	164.65	152.59
Total Expenses	373.17	364.79	320.20	1320.88	1428.11
3 Total Profit before Exceptional Items and Tax	54.99	19.22	21.70	105.37	71.34
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00
5 Total Profit before Tax	54.99	19.22	21.70	105.37	71.34
6 Tax Expense					
7 Current Tax	10.50	5.50	5.10	23.00	17.50
8 Deferred Tax	(0.58)	0.00	(0.87)	(0.58)	(0.87)
9 Total Tax Expenses	9.92	5.50	4.23	22.42	16.63
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement		0.00	0.00	0.00	0.00
11 Net Profit Loss for the period from continuing operations	45.07	13.72	17.47	82.95	54.71
12 Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0.00
13 Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00
14 Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00
15 Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00
16	45.07	13.72	17.47	82.95	54.71
17 Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0.00
18 Total Comprehensive Income for the Period	45.07	13.72	17.47	82.95	54.71



Jadhav Arun

19	Total profit or loss attributable to					
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00
20	Total comprehensive income for the period attributable to					
	Comprehensive Income for the period attributable to the owners of parents		0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests		0.00	0.00	0.00	0.00
21	Details of Equity Share Capital					
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00
22	Details of Debt Securities					
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00
24	Debenture Redemption Reserve	0.00	0.00	0.00	0.00	0.00
25	Earnings Per Share					
(i)	Earnings Per Share for continuing operations					
	Basic Earnings / (Loss) per share from continuing operations	1.51	0.46	0.58	2.77	1.83
	Diluted Earnings / (Loss) per share from continuing operations	1.51	0.46	0.58	2.77	1.83
(ii)	Earnings Per Share for discontinued operations					
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00
(iii)	Earnings per Equity Share					
	Basic Earnings / (Loss) per share from continuing and discontinued operations	1.51	0.46	0.58	2.77	1.83
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	1.51	0.46	0.58	2.77	1.83
26	Debt Equity Ratio	0.00	0.00	0.00	0.00	0.00
27	Debt Service Coverage Ratio	0.00	0.00	0.00	0.00	0.00
28	Interest Service Coverage Ratio	0.00	0.00	0.00	0.00	0.00

NOTES	
1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on June 30, 2021.	
2. Results for the quarter and year ended 31st March, 2021, are in compliance with Indian Accounting Standards ('IndAS') notified by the Ministry of Corporate Affairs.	
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment. Hence no segment wise figures are published.	
4. The figures for the quarter ended 31st March, 2021, are balancing figures between audited figures in respect of full financial year ended 31st March, 2021, and the published year to date figures upto the third quarter ended 31st December, 2020, which have been regrouped / rearranged wherever necessary.	
5. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.	
For, ISHITA DRUGS AND INDUSTRIES LIMITED	
 	
JAGDISH AGRAWAL	
MANAGING DIRECTOR	
Place	Ahmedabad
Date	30-Jun-21
DIN: 01031687	

ISHITA DRUGS AND INDUSTRIES LIMITED
CIN: L24231GJ1992PLC017054
Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170
Website: www.ishitadrugs.com
Contact: +91 7226995613

Statement of Assets and Liabilities

Amount in Lakhs

Particulars	Year Ended		Previous Year Ended	
	12 Months Ended		12 Months Ended	
	Audited		Audited	
	31-03-21		31-03-20	
ASSETS				
1	Non-current assets			
	Property, plant and equipment	99.58	113.70	
	Capital work-in-progress			
	Investment property			
	Goodwill			
	Other intangible assets			
	Intangible assets under development			
	Biological assets other than bearer plants			
	Investments accounted for using equity method			
	Non-current financial assets	99.58	113.70	
	Non-current investments	22.59	20.68	
	Trade receivables, non-current			
	Loans, non-current			
	Other non-current financial assets	5.07	5.06	
	Total Non-current financial assets	27.66	25.74	
	Deferred tax assets (net)			
	Other non-current assets			
	Total Non-current Assets	127.24	139.44	
2	Current assets			
	Inventories	65.44	58.09	
	Current financial assets			
	Current investments	288.50	508.66	
	Trade receivables, current	152.38	131.10	
	Cash and cash equivalents	175.32	40.18	
	Bank balance other than cash and cash equivalents	78.51	59.78	
	Loans, current	36.47	14.44	
	Other current financial assets	2.63	2.84	
	Total current financial assets	733.81	757.00	
	Current tax assets (net)			
	Other current assets			
	Total Current Assets	0.00	0.00	
3	Non-current assets classified as held for sale			
4	Regulatory deferral account debit balances and related deferred tax Assets			
	TOTAL ASSETS	926.49	954.54	



Jaydevi

EQUITIES AND LIABILITIES			
1	Equity		
	Equity attributable to owners of Parent		
	Equity share capital	299.03	299.03
	Other equity	480.04	397.08
	Total Equity attributable to owners of Parent	779.07	696.11
	Non controlling interest		
	Total Equity	779.07	696.11
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current	0.00	4.19
	Trade payables, non-current		
	Other non-current financial liabilities		
	Total Non-current financial liabilities	0.00	4.19
	Provisions, non-current		
	Deferred tax liabilities (net)	4.11	4.70
	Deferred government grants, Non-current Other non-current liabilities		
	Total Non-current liabilities	4.11	4.70
	Current liabilities		
	Current financial liabilities		
	Borrowing, current	0.00	16.56
	Trade payables, current	98.24	189.36
	Other current financial liabilities	4.19	8.05
	Total current financial liabilities	102.44	213.97
	Other current liabilities	10.91	9.52
	Provisions, current	7.66	7.17
	Current tax liabilities (Net)	22.31	18.88
	Deferred government grants, Current		
	Total current liabilities	40.88	35.57
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	Total Liabilities	0.00	0.00
	Total Equity and Liabilities	926.49	954.54

For, ISHITA DRUGS AND INDUSTRIES LIMITED

Jagdish Agrawal



JAGDISH AGRAWAL

MANAGING DIRECTOR

Place Ahmedabad

Date 30-Jun-21

DIN: 01031687

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

AUDITED CASH FLOW STATEMENT

Sr. No.	Particulars	Audited Year Ended 31.03.2021 Rs. In Lakhs	Audited Year Ended 31.03.2020 Rs. In Lakhs
(A)	Cash flow from operating activities :		
	Profit before tax	105.37	71.34
	Add : Depreciation	14.61	17.75
	Interest & Other financial charges	3.16	3.47
	Less : Interest received	4.03	4.56
	Dividend received	0.01	0.01
	Income from Investments	27.31	11.67
	Operating profit before change in working capital	91.79	76.33
	Add : Trade Debtors	(21.28)	(13.06)
	Decrease/(Increase) in Inventory	(7.35)	15.78
	Decrease/(Increase) in Loans and advances	(21.83)	(1.05)
	Less : Provision for Taxation	23.00	17.50
	Decrease/(Increase) Shore Term Provision	(1.88)	0.46
	Decrease/(Increase) Trade Creditors, Current liabilities & Provisions	87.69	(44.72)
	Net cash generated from operating activities (A)	(67.48)	104.75
(B)	Cash inflow from investing activities :		
	Add : Investment sold / (purchased)	218.26	(125.55)
	Dividend received	0.01	0.01
	Income from Investments	27.31	11.67
	Less : Investment in fixed assets	0.49	1.46
	Net cash generated from investing activities (B)	245.09	(115.33)
(C)	Cash flow from financial activities :		
	Add : Interest received	4.03	4.56
	Borrowings	(24.61)	8.34
	Less : Interest & Other financial charges	3.16	3.47
	Net cash generated from financial activities (C)	(23.74)	9.42
	Net Increase/(decrease) in Cash & Cash Equivalents (A+B+C)	153.87	(1.15)
	Opening balance of Cash and cash equivalents	99.96	101.11
	Closing balance of Cash and cash equivalents	253.83	99.96
	Net Increase/(decrease) in Cash & Cash Equivalents	153.87	(1.15)

Note : Figures in bracket indicate negative value

Correctly extracted from Audited accounts of the Company

For, ISHITA DRUGS AND INDUSTRIES LIMITED

Jagdish Agrawal



JAGDISH AGRAWAL

MANAGING DIRECTOR

DIN: 01031687

Place Ahmedabad

Date 30-Jun-21



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Date: 30.06.2021

To,
The Department of Corporate Services,
The BSE Limited
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

Security Code: 524400

Dear Sir/Madam,

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI(Listing Obligation and Disclosure Requirements) Regulations, 2015 w.r.t. Audit Report with unmodified opinion

Pursuant to Regulation 33(3)(d) of SEBI(Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company, have issued an Audit report with unmodified opinion on Standalone Annual Financial Results of the Company for the year ended on 31st March, 2021.

Kindly take the above on your records.

Thanking You

For Ishita Drugs and Industries Limited





Authorized Signatory

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359